Endpoint Adjudication Committee (CEC)

An Endpoint Adjudication Committee (EAC) — often called a Clinical Events Committee (CEC) — is an independent group of clinical experts, typically blinded to each participant’s treatment assignment, that reviews reported clinical events against pre-specified, standardized criteria and issues a formal, documented classification of whether each event qualifies as a study endpoint. It exists to remove the variability that creeps in when an outcome depends on clinical judgment — a stroke, a myocardial infarction, a cause of death, a disease progression event — rather than a single unambiguous lab value, and it matters most in multi-site, multinational, or partially unblinded trials where local diagnostic practice and terminology genuinely differ from site to site.

Why adjudication exists

Trials that report a composite or clinically complex primary endpoint — most visibly cardiovascular outcomes trials tracking MACE (Major Adverse Cardiovascular Events: death, MI, stroke, and related events) — cannot rely solely on each site’s own diagnosis, because diagnostic thresholds and documentation habits vary by site, country, and clinician. Left uncorrected, that variability becomes differential misclassification risk that can bias a trial’s result even when nothing about the intervention itself changed. A CEC standardizes the determination after the fact: every candidate event is re-reviewed against the same fixed, protocol-specified definition by reviewers who did not make the original bedside call.

Blinding is the second half of the rationale. In an open-label or otherwise partially unblinded trial, a CEC blinded to treatment assignment functions as a substitute for blinded outcome assessment — the committee’s classification cannot be influenced by knowledge of which arm a participant was in, even though the treating site-level clinicians knew.

How the process works

A trial’s protocol and a dedicated adjudication charter define, in advance, which events trigger a referral to the committee — commonly any event that could plausibly meet the endpoint definition, flagged either automatically (e.g. any serious adverse event coded to a relevant category) or by site/monitor report. Source documents supporting the event (discharge summaries, imaging, lab values, autopsy reports where relevant) are compiled and, where the committee is blinded, stripped of treatment-arm identifiers before circulation. Typically two reviewers assess the case independently against the pre-specified criteria; disagreement is resolved by a third reviewer or full-committee consensus, and every determination — including the reasoning — is documented for the trial master file and eventual regulatory submission.

How a CEC differs from a DSMB / IDMC

The two functions are easy to conflate because both are independent, protocol-governed committees sitting outside the sponsor and site teams, but they do different jobs. A Data Safety Monitoring Board (DSMB) — called an Independent Data Monitoring Committee (IDMC) in EMA usage — has deliberately unblinded, arm-by-arm access to interim safety and efficacy data, and its job is a running benefit-risk judgment about whether the trial as a whole should continue, be modified, or stop early. A CEC, by contrast, is typically blinded to treatment arm and adjudicates individual events one at a time against fixed criteria; it does not perform comparative interim analysis and does not recommend stopping a trial. FDA guidance on data monitoring committees makes this separation explicit, cautioning against a single body serving both roles precisely because a DSMB’s unblinded comparative access could compromise the neutrality that endpoint adjudication depends on.

Governance: the adjudication charter

A CEC operates under a written charter — analogous in function to a DSMB charter — that specifies: committee membership and the clinical qualifications required for each role, conflict-of-interest declarations, the event-trigger criteria that route a case to the committee, the source documents required for review, the step-by-step review and reconciliation process (independent primary review, tie-break or consensus mechanism), timelines for turnaround, and how determinations are recorded and communicated back to the sponsor without unblinding treatment assignment. Sponsors commonly submit this charter to regulators alongside the protocol, since it documents how a subjective-seeming endpoint was in fact operationalized consistently across the trial.

Where adjudication appears in regulatory guidance

ICH E6 Good Clinical Practice sets the general expectation that trial conduct and data — including how endpoints are evaluated — be documented, verifiable, and free from bias, without prescribing a specific adjudication-committee structure. FDA has been more explicit in specific domains: its guidance on data monitoring committees distinguishes DMC and endpoint-adjudication functions as described above, and its guidance on imaging endpoint process standards addresses the closely related practice of blinded independent central review (BICR) — independent, blinded re-reads of imaging data, most often used to adjudicate progression or response endpoints in oncology trials, following the same underlying logic of independent, blinded, criteria-based review applied to a different evidence type.

Frequently asked questions

Is an endpoint adjudication committee the same as a DSMB?

No. Both are independent, protocol-governed committees, but a DSMB has unblinded comparative access across arms to make an ongoing trial-continuation recommendation, while a CEC is typically blinded and classifies individual events against fixed criteria without a stopping-decision role. See the comparison above.

Who sits on a CEC?

Clinicians with relevant subspecialty expertise for the endpoint being adjudicated — cardiologists for a cardiovascular-outcomes trial’s MACE endpoint, neurologists for stroke, oncologists/radiologists for tumor-response endpoints — appointed independently of the sponsor and site investigators, with documented conflict-of-interest declarations per the adjudication charter.

Is adjudication required on every trial?

No. It is used selectively, most often for trials with composite or clinically complex primary/secondary endpoints, open-label or partially unblinded designs, or regulatory submissions where consistent, defensible endpoint determination materially affects the trial’s evidentiary weight — not for trials where the endpoint is a single objective, unambiguous measurement.

What happens when adjudicators disagree?

The charter’s pre-specified reconciliation process governs it — commonly referral to a third independent reviewer or a full-committee consensus discussion — and the outcome, including the path taken to reach it, is documented as part of the trial’s audit trail.